Loading Discussion

If pharmaceutical companies know that doctors are now focusing on how treatments interact with race, they are likely to diversify the group of patients they use in clinical trials so that a new drug could be considered by a doctor when treating someone of any race. This would provide important information about the real efficacy of drugs, as clinical trial groups in the status quo tend to significantly underrepresent minorities.